Zist Takhmir Company’s New Pharmaceutical Products Unveiled in Pardis Technology Park

The new products of Zist Takhmir Company, a member of Pardis Technology Park, were unveiled in the presence of Abbas Aliabadi, Minister of Industry, Mine and Trade, Rouhollah Dehqani Firouzabadi, Iran’s Vice President for Science, Technology and Knowledge-based Economy and Heider Mohammadi, Head of Food and Drug Administration of the Islamic Republic of Iran.

These 6 drugs and 3 active ingredients are used in the field of cancer and skin diseases treatment.

Referring to the company’s activity in producing special medicines, CEO of Zist Takhmir Company Sahar Bahmani said that the unveiled products are used in cancer treatment and probiotics, which are special drugs and have been released to the market after technical procedures.

Regarding the production line, she said that the pharmaceutical raw materials are classified as high-risk materials in terms of health exposure limits. Production and work with these materials require international work requirements and 3-5 OEB (Occupational Exposure Band).

These requirements have been implemented by installing and establishing and verifying the quality of special equipment such as optimized isolators for all stages of synthesis of raw materials with OEB 4, 5, she noted.

Thanks to the GMP certificate and launching this line, the company can save $43m by producing Edaravone, Tofacitinib citrate and Apremilast in the first year.